ADRX

Sinker

ADARx Pharmaceuticals, Inc. · Healthcare · United States · $1.9B cap · $6.6M/day traded

$14.20 -4.8% · close 13 Nov · scored 14 Nov

Sinker: Weak business, rich price and weak momentum. Nothing here to keep it afloat.

9
Score
Get score and insider alerts
Quality
35
Value
22
Momentum
23

As of 14 Nov 2026, the MoatMap Score for ADARx Pharmaceuticals, Inc. (ADRX) is 9/100, ranked against 25,000+ stocks in 38 markets (Quality 35, Value 22, Momentum 23, each scored against its sector).

Does the score work? Each tenth of the ranking, tracked monthly. See the record →

P/E (TTM)
—
peers 26.6x
ROE
—
peers -29.9%
D/E
0.1x
peers 0.2x
Dividend %
—
trailing yield

ABOUT ADARX PHARMACEUTICALS, INC.

Read

ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases.

FINANCIAL SUMMARY (USD)

Year20242025TTM2026E2027EFwd CAGR
Income and shares
Revenue—3.4M6.1M6.2M39.9M240.0%
Net marginn/m-2119.1%————
EPS-0.62-0.97-1.16-2.03-1.45—
Share count102.2M102.2M110.7M———
Balance sheet
Debt4.3M7.7M6.9M———
Equity-137.1M-202.3M————
Debt/equityn/mn/m————
Cash flow
Op. cash flow-48.6M262.3M-88.3M———
Cash flow marginn/m7604.8%-1441.5%———
Investing CF39.5M-209.9M————
Financing CF0.2M97.0K————
PRICE (1Y) · USD-25.5%
13.214.716.117.619.05 Oct26 Oct13 Nov

Price checkNo read yetExperimental

Not enough steady price history for a read yet.

How this is worked out

The Price check reads only the chart, the price side of the Momentum score in words; it is not the MoatMap Score.

  • Still falling: It set a new 52-week low in the last two weeks, after a deep fall.
  • Finding a floor: It fell hard, but has set no new low for more than two weeks.
  • Turning up: It has climbed off its low and is back above a rising 50-day average.
  • In an uptrend: It is near its 52-week high and above its 200-day average.
  • No clear trend: None of the above: no recent deep fall and no steady climb.
  • No read yet (this stock): Not enough price history yet: it needs a year of trading.

In past US falls, waiting for Turning up cut the chance of another 20% drop from 42% to 33%. Returns were no better, and 33% of turns failed.

The exact rules

Still falling is a new 52-week low in the last two weeks, at least 25% below the high, with the low set after the high. Finding a floor is the same fall with no new low in the last two weeks. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average, with the 50-day average above the 200-day, and within 15% of the high. No clear trend is everything else. No read yet is under 252 trading days of history, or missing data. A new state shows once it has held for three trading days.

In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.

Rules fixed before any data was fetched. Describes the chart, not a recommendation.

Close
$14.20
RSI (14)
30.5

SCORE BREAKDOWN

Quality
35
ROIC
-18.5%30.0
ROE
—N/A
GP/Assets
-16.5%4.7
Op. Margin
-1735.0%3.7
FCF/Assets
n/mN/A
Piotroski
677.5
Int. Cover
—N/A
D/E Ratio
0.06x68.1
Current Ratio
12.98x91.5
Value
22
P/E (TTM)
—N/A
EV/EBITDA
-13.8x25.0
P/FCF
n/mN/A
P/B
-0.6x25.0
P/S
256.6x4.3
Div Yield
—N/A
Momentum
23
52W High %
—N/A
RS 6M
—N/A
SMA 50/200
—N/A
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
-25%12.3
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$1.9B
P/E (Forward)
-9.8x
Gross Margin
—

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ADRX are excluded.

TickerCompanyMkt CapScore
ADRXADARx Pharmaceuticals, Inc.(you)$1.9B9
MLYSMineralys Therapeutics, Inc.$1.8B6
STOKStoke Therapeutics, Inc.$1.6B9
IMNMImmunome, Inc.$2.1B11
VERAVera Therapeutics, Inc.$2.0B6
RAREUltragenyx Pharmaceutical Inc.$1.5B10
NTLAIntellia Therapeutics, Inc.$1.6B7
LYCALycia Therapeutics, Inc.$1.6B7
KLRAKailera Therapeutics, Inc.$1.7B13
GENBGenerate Biomedicines, Inc.$1.6B5

Peer medians: ROE -29.9% · P/E 26.6x · Gross margin 63.3%

Company Deep Dive

A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.

Request Deep Dive(50 Feathers)

ADARx Pharmaceuticals, Inc. (ADRX): Stock Score Summary

ADARx Pharmaceuticals, Inc. (ADRX) has a MoatMap Score of 9/100 based on Quality (35/100), Value (22/100), and Momentum (23/100) factor scores.

ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases.

Director dealings

From 2 Jan 2026 to 13 Nov 2026, MoatMap's records hold no sales and 4 purchases of ADARx Pharmaceuticals, Inc. (ADRX) shares by its directors. The largest: George Simeon bought 1,600,000 shares at $17.00 on 28 Sep 2026 (about $27.2M).

  • 28 Sep 2026: Chimovits Erez bought 61,516 shares at $17.00 (about $1.0M)
  • 28 Sep 2026: George Simeon bought 1,600,000 shares at $17.00 (about $27.2M)
  • 28 Sep 2026: GORDON CARL L bought 950,000 shares at $17.00 (about $16.1M)
  • 28 Sep 2026: ORBIMED ADVISORS LLC bought 950,000 shares at $17.00 (about $16.1M)
ADRX insider filings, last 180 days

Key Financial Metrics

Price$14.20
Market Cap$1.9B
P/E (Forward)-9.79
Price/Book-0.64
Return on Invested Capital-18.5%
Debt/Equity0.06x
Operating Margin-1735.0%
Revenue Growth258.7%
Free Cash Flow$259M

ADARx Pharmaceuticals, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is ADARx Pharmaceuticals, Inc.’s (ADRX) MoatMap Score?
The MoatMap Score for ADARx Pharmaceuticals, Inc. (ADRX) is 9/100. It is a composite of Quality (35), Value (22), and Momentum (23), each scored against its sector. The composite is then ranked across MoatMap’s universe of 25,000+ stocks.
Does ADARx Pharmaceuticals, Inc. have an economic moat?
ADARx Pharmaceuticals, Inc. (ADRX) has a Quality factor score of 35/100. Quality blends several measures of profitability and financial strength, led by gross profit to assets, return on invested capital and free cash flow to assets. A high score describes the financial record a durable advantage tends to leave; it does not prove a moat.
What sector is ADARx Pharmaceuticals, Inc. in?
ADARx Pharmaceuticals, Inc. (ADRX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).